Effect of local application of Glycyrrhiza glabra and eucalyptus extract for the prevention of Mucositis

Effect of local application of Glycyrrhiza glabra and eucalyptus extract for the prevention of chemoradiation Induced Oral Mucositis in head and neckmalignancies

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190415043279N4

Enrollment

Registered

2020-06-14

Start date

2019-06-22

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Mucositis. Stomatitis and related lesions

Interventions

Intervention 1: Intervention group: The recipient of the solution containing Glycyrrhiza glabra and eucalyptus extract, It is recommended to use 20 cc of it as a gargle for 30 seconds three times a da

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Head and neck carcinoma Full awareness Oral mucosal health

Exclusion criteria

Exclusion criteria: History of allergy to medicinal plants High blood pressure Diabetes Autoimmune diseases Cardiovascular disease Neutropenia The presence of mucosal lesions in the mouth Previous history of radiotherapy and chemotherapy Chronic liver diseases Active collagen vascular disease Non-use of drugs; alcohol; cigarettes

Design outcomes

Primary

Measure	Time frame
Incidence of severe mucositis (Grade 3=). Timepoint: The beginning of the intervention, every week continuously, the end of the intervention, one week after the end of the intervention. Method of measurement: Clinical examination by an oncologist and determination of mucositis grading using (NCI-CTCAE) version 4.	—

Secondary

Measure	Time frame
Need for painkillers during treatment. Timepoint: During the course of treatment. Method of measurement: Check list.;The incidence of any degree of mucositis. Timepoint: During the course of treatment. Method of measurement: Examination by an oncologist and registration in the checklist.;Time of onset of mucositis. Timepoint: When mucositis begins. Method of measurement: Examination by an oncologist and registration in the checklist.;Duration of mucositis. Timepoint: Time from onset to resolution of mucositis. Method of measurement: Examination by an oncologist and registration in the checklist.	—

Measure

Time frame

Need for painkillers during treatment. Timepoint: During the course of treatment. Method of measurement: Check list.;The incidence of any degree of mucositis. Timepoint: During the course of treatment. Method of measurement: Examination by an oncologist and registration in the checklist.;Time of onset of mucositis. Timepoint: When mucositis begins. Method of measurement: Examination by an oncologist and registration in the checklist.;Duration of mucositis. Timepoint: Time from onset to resolution of mucositis. Method of measurement: Examination by an oncologist and registration in the checklist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBayazid Ghaderi

Sanandaj University of Medical Sciences

bayazid.g@yahoo.com+98 87 3366 4645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026